Pear Therapeutics (NASDAQ:PEAR – Get Rating)‘s stock had its “buy” rating reiterated by Chardan Capital in a report released on Monday, PriceTargets.com reports. Separately, Citigroup raised their target price on shares of Pear Therapeutics from $10.00 to $11.00 and gave the stock a “buy” rating in a report on Tuesday, May 17th. One equities research […]
Pear Therapeutics (NASDAQ:PEAR – Get Rating) and Better Therapeutics (NASDAQ:BTTX – Get Rating) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, dividends, earnings, risk, analyst recommendations, valuation and profitability. Profitability This table compares Pear Therapeutics and Better Therapeutics’ […]
Pear Therapeutics (NASDAQ:PEAR – Get Rating) and LifeStance Health Group (NASDAQ:LFST – Get Rating) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, analyst recommendations and risk. Profitability This table compares Pear Therapeutics and LifeStance Health […]
Shares of Pear Therapeutics, Inc. (NASDAQ:PEAR – Get Rating) have been given an average recommendation of “Buy” by the six brokerages that are covering the firm, Marketbeat.com reports. One analyst has rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 12 month price objective among […]
Wall Street brokerages predict that Pear Therapeutics, Inc. (NASDAQ:PEAR – Get Rating) will post ($0.25) earnings per share (EPS) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Pear Therapeutics’ earnings. The company is expected to announce its next earnings results on Monday, January 1st. According to Zacks, […]